Who is sponsoring NCT04971694?

NCT04971694 is sponsored by Pediatrix.

What drugs are being tested in NCT04971694?

Interventions in NCT04971694: No interventions or procedures.

What condition does NCT04971694 study?

NCT04971694 studies BPD - Bronchopulmonary Dysplasia.

Is NCT04971694 still recruiting?

NCT04971694 is currently completed. Last updated 19 November 2024.

Last reviewed 2024-11-19 · How we verify

NCT04971694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Steroid, Diuretic, and Fluid Use on BPD Outcomes

Completed Last updated 19 November 2024

What this trial tests

trial testing No interventions or procedures in BPD - Bronchopulmonary Dysplasia in 175 participants. Completed in 6 July 2024.

Timeline

30 August 2021

Primary endpoint
19 September 2022

6 July 2024

Quick facts

Lead sponsor	Pediatrix
Status	Completed
Study type	OBSERVATIONAL
Enrollment	175
Start date	30 August 2021
Primary completion	19 September 2022
Estimated completion	6 July 2024
Sites	1 location across United States

Drugs / interventions tested

No interventions or procedures

Conditions studied

BPD - Bronchopulmonary Dysplasia — all drugs for BPD - Bronchopulmonary Dysplasia →

Sponsor

Pediatrix — full company profile →

Who can join

Eligibility, any sex, with BPD - Bronchopulmonary Dysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Assess the impact of steroid, diuretic, and fluid practices on BPD outcomes in extreme premature infants in the Banner - University Medical Center Phoenix (BUMCP) neonatal intensive care unit (NICU).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for BPD - Bronchopulmonary Dysplasia

Currently open trials in the same condition.

NCT06788470 — Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulm · Phase 1, PHASE2 · recruiting
NCT06065215 — Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM) · recruiting

Other Pediatrix trials

Trials by the same sponsor.

NCT04977817 — Probiotics/TPN in the NICU · completed
NCT04513691 — A Chart Review of Newborns With the Presence of Confirmed or Suspected Maternal Chorioamnionitis and Utilization of the · completed
NCT04085978 — Effects of a Hypoglycemia Protocol With Glucose Gel on Neonatal Intensive Care Unit (NICU) Admission · terminated
NCT03946631 — GDM Post Partum Screening · terminated
NCT03414671 — The Effect of Standardizing the Definition of a Clinically Significant Cardiopulmonary Event on Length of Stay · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04971694 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pediatrix
Last refreshed: 19 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing